First Time Loading...

Omega Therapeutics Inc
NASDAQ:OMGA

Watchlist Manager
Omega Therapeutics Inc Logo
Omega Therapeutics Inc
NASDAQ:OMGA
Watchlist
Price: 3.65 USD 2.82% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

OMGA's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Omega Therapeutics, Inc. engages in the development of DNA-sequence-targeting, mRNA-encoded therapeutics. [ Read More ]

The intrinsic value of one OMGA stock under the Base Case scenario is 0.43 USD. Compared to the current market price of 3.65 USD, Omega Therapeutics Inc is Overvalued by 88%.

Key Points:
OMGA Intrinsic Value
Base Case
0.43 USD
Overvaluation 88%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Omega Therapeutics Inc

Backtest OMGA Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling OMGA stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Omega Therapeutics Inc

Current Assets 101.9m
Cash & Short-Term Investments 89.3m
Receivables 1.4m
Other Current Assets 11.2m
Non-Current Assets 115.9m
PP&E 115.5m
Other Non-Current Assets 400k
Current Liabilities 26.8m
Accounts Payable 2.4m
Accrued Liabilities 19.3m
Other Current Liabilities 5.1m
Non-Current Liabilities 115m
Long-Term Debt 15.9m
Other Non-Current Liabilities 99.1m
Efficiency

Earnings Waterfall
Omega Therapeutics Inc

Revenue
2.9m USD
Operating Expenses
-113.4m USD
Operating Income
-110.5m USD
Other Expenses
2.5m USD
Net Income
-108.1m USD

Free Cash Flow Analysis
Omega Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

OMGA Profitability Score
Profitability Due Diligence

Omega Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Exceptional 1-Year Revenue Growth
Negative Operating Income
Negative Net Income
Negative ROE
21/100
Profitability
Score

Omega Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

OMGA Solvency Score
Solvency Due Diligence

Omega Therapeutics Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Short-Term Solvency
Low D/E
Long-Term Solvency
49/100
Solvency
Score

Omega Therapeutics Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

OMGA Price Targets Summary
Omega Therapeutics Inc

Wall Street analysts forecast OMGA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OMGA is 12.24 USD with a low forecast of 10.1 USD and a high forecast of 15.75 USD.

Lowest
Price Target
10.1 USD
177% Upside
Average
Price Target
12.24 USD
235% Upside
Highest
Price Target
15.75 USD
332% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

OMGA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

OMGA Price
Omega Therapeutics Inc

1M 1M
-11%
6M 6M
+70%
1Y 1Y
-42%
3Y 3Y
-79%
5Y 5Y
-79%
10Y 10Y
-79%
Annual Price Range
3.65
52w Low
1.35
52w High
9.66
Price Metrics
Average Annual Return -39.12%
Standard Deviation of Annual Returns 25.22%
Max Drawdown -95%
Shares Statistics
Market Capitalization 201.1m USD
Shares Outstanding 55 141 800
Percentage of Shares Shorted 19.12%

OMGA Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Omega Therapeutics Inc Logo
Omega Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

201.1m USD

Dividend Yield

0%

Description

Omega Therapeutics, Inc. engages in the development of DNA-sequence-targeting, mRNA-encoded therapeutics. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2021-07-30. The firm is engaged in a systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming platform. Its OMEGA Epigenomic Programming platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth, and differentiation to cell death. The company has deciphered the three-dimensional architecture of the human genome and its accompanying regulators, which are organized into distinct and evolutionarily conserved structures called Insulated Genomic Domains (IGDs). The OMEGA platform enables to systematically identify and validate thousands of DNA-sequence-based epigenomic zip codes within IGDs. Its pipeline consists of early-stage, preclinical programs that span regenerative medicine, multigenic diseases including immunology, oncology, and select monogenic diseases.

Contact

MASSACHUSETTS
Cambridge
20 Acorn Park Drive
+16179494360.0
https://omegatherapeutics.com/

IPO

2021-07-30

Employees

60

Officers

President, CEO & Board Director
Mr. Mahesh Karande
Chief Legal & Administrative Officer and Secretary
Ms. Ling Zeng Esq., J.D.
Chief Medical Officer
Dr. Yan Moore M.D.
Chief Financial Officer
Mr. Joshua Reed M.B.A.
Senior VP and Head of Technical Operations & Quality
Dr. Sivakesava Sakhamuri Ph.D.
Chief Scientific Officer
Dr. Thomas McCauley
Show More
Chief People Officer
Mr. Anthony Mullin
VP and Head of Computational Genomics & Data Sciences
Mr. Charles O'Donnell Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one OMGA stock?

The intrinsic value of one OMGA stock under the Base Case scenario is 0.43 USD.

Is OMGA stock undervalued or overvalued?

Compared to the current market price of 3.65 USD, Omega Therapeutics Inc is Overvalued by 88%.